Introduction
Macrophage activation syndrome (MAS) is a severe complication of systemic juvenile idiopathic arthritis (s-JIA), which is characterized clinically by fever, hepatosplenomegaly, lymphadenopathy, profound depression of all three blood cell lines, deranged liver function, intravascular coagulation and central nervous system dysfunction [1] . Examination of bone marrow shows a feature of numerous macrophages exhibiting haemophagocytosis. MAS should be considered among the secondary causes of haemophagocytic lymphohistiocytosis (HLH) because of its close resemblance to a group of HLH syndromes [2] .
MAS is a potentially life-threatening disease; therefore, a timely and prompt diagnosis is essential to initiate lifesaving treatment. However, it can be difficult to distinguish MAS from s-JIA flares, sepsis or other secondary HLH. Differentiation of MAS from these conditions is essential for selection of an appropriate therapeutic intervention in a timely fashion. However, there is no definitive clinical or laboratory parameter that establishes MAS diagnosis.
Recent investigations into the pathophysiology of s-JIA have focused upon mediators of the innate immune system. In particular, interleukin (IL)-1, IL-6 and IL-18 play an important role in the pathogenesis of s-JIA [3] . The hallmark of MAS is an uncontrolled and dysfunctional immune response, which leads to marked hypercytokinaemia [4] . In the development of MAS from s-JIA, tumour necrosis factor (TNF)-a, interferon (IFN)-g and IL-18 become dominant, rather than IL-6 and IL-1b. Therefore, serial monitoring of serum levels of these cytokines might be useful for the diagnosis of MAS.
We have reported previously that serum levels of IL-18 are elevated highly in patients with s-JIA, and abnormal production of IL-18 appears to be specific to s-JIA [5] .
Furthermore, we reported serum IL-18 levels during the active phase in s-JIA patients who later developed MAS were significantly higher than those without MAS [6] . However, there were no significant differences in serum IL-18 levels in s-JIA patients with MAS measured either before or during MAS. These findings indicate that serum IL-18 levels are a useful predictor of MAS development during the acute phase, but they are not valuable in the diagnosis of transition to MAS from acute phase of s-JIA.
Soluble tumour necrosis factor receptor (sTNF-R) I and II play an important role as modulators of the biological function of TNF-a. In various pathological conditions, sTNF-RI/II mediates a host response and determines the course and outcome of disease by interacting with TNF-a. Measurement of sTNF-RI/II has some advantages over TNF-a. TNF-a is cleared rapidly from the circulation and is frequently undetectable, whereas sTNF-RI/II are very stable and can also be determined in stored serum [7] . Furthermore, serum levels of sTNF-RI/II correlate well with those of TNF-a [8, 9] .
To investigate the clinical significance of sTNF-RII/I as an indicator of disease activity and the diagnosis for MAS, we measured serum sTNF-RI and II levels in patients with s-JIA and determined their correlation with measurements of disease activity and severity. Furthermore, we measured serum IL-18 levels in patients with Epstein-Barr virusinduced haemophagocytic lymphohistiocytosis (EBV-HLH) and compared these in levels in patients with MAS. [11, 12] . The criteria for acute phase s-JIA were defined as follows: active arthritis, fever, rash, hepatosplenomegaly, generalized lymphadenopathy, active uveitis and serositis, along with increased erythrocyte sedimentation rate and C-reactive protein levels. Patients with sepsis or severe bacterial infection were excluded. Some patients had minimal joint disease at the onset of s-JIA and the presence of arthritis was confirmed later. The clinical characteristics of s-JIA patients during the acute phase are shown in Table 1 . Of a total of 104 patients, 72 had no treatment, while the other 32 patients were treated with prednisolone (PSL). In addition to PSL, eight patients were also treated with cyclosporin, one was treated with methotrexate and tacrolimus and four were treated with tocilizumab. The clinical characteristics of MAS patients are shown in Supporting information, Table S1 . Of the 29 patients, 10 had no treatment, 18 were treated with PSL, one was treated with methylprednisolone pulse therapy, four were treated with cyclosporin and six were treated with tocilizumab. Serum was separated from cells, divided into aliquots, frozen and stored at 2808C until analysed. This study was approved by the Institutional Review Board at Kanazawa University (Ethics Committee approval number 1403), and all participants gave informed consent.
Materials and methods

Patients and samples
Measurement of serum cytokine levels
Serum levels of sTNF-RI and II, IL-18, IL-6 and neopterin were measured using commercial enzyme-linked immunosorbent assay, according to the manufacturer's instructions (TNF-a receptor types I and II, IL-6: R&D Systems, Inc, Minneapolis, MN, USA; IL-18, MBL: Nagoya, Japan, neopterin; IBL: Hamburg, Germany).
Statistical analysis
Multiple comparisons among groups were analysed using the Kruskal-Wallis test. Within-group comparisons were analysed using the Mann-Whitney U-test. Comparison of the sTNF-RII/I ratio between the acute phase of s-JIA and MAS was analysed using a paired t-test. Correlations were expressed using a Spearman's rank correlation coefficient. For the analysed measures, P-values less than 0Á05 were considered significant.
Results
Characteristic elevation of serum sTNF-RII levels and sTNF-RII/I ratio in MAS complicating s-JIA
We measured serum sTNF-RI and II levels in patients with s-JIA during the acute and MAS phases and compared these with levels seen in patients with EBV-HLH or KD. As shown in Fig. 1a , compared with HCs (median 5 990; range 5 490-1940 pg/ml), serum sTNF-RI levels were elevated significantly during the acute phase in patients with s-JIA (acute) (2640; 900-8250 pg/ml, P < 0Á0001), MAS (3600; 770-7700 pg/ml, P < 0Á0001), EBV-HLH (3200; 1750-9200 pg/ml, P < 0Á0001) and KD (2710; 1380-6200 pg/ml, P < 0Á0001). Serum sTNF-RI levels were elevated significantly in MAS compared with acute; however, there was an overlap in serum sTNF-RI levels. There were no significant differences among MAS, EBV-HLH and KD.
As shown in Fig. 1b , compared with HCs (2095; 1050-3500 pg/ml), serum sTNF-RII levels were elevated significantly in acute (6400; 1060-34 300 pg/ml, P < 0Á0001), MAS (25 000; 4300-66 300 pg/ml, P < 0Á0001), EBV-HLH (36 500; 12 300-115 000 pg/ml, P < 0Á0001) and KD (8600; 3250-28 000 pg/ml, P < 0Á0001). Serum sTNF-RII levels were elevated significantly in MAS compared with acute (P < 0Á0001) and KD (P < 0Á0001). Serum sTNF-RII levels were elevated significantly in EBV-HLH compared with acute (P < 0Á0001) and KD (P < 0Á0001). Serum sTNF-RII levels were elevated significantly in KD compared with acute (P < 0Á05). There were also no significant differences between MAS and EBVHLH.
As shown in Fig. 1c , compared with HCs (2Á19; 1Á02-5Á37), the sTNF-RII/I ratio was elevated significantly in MAS (6Á33; 2Á83-22Á71, P < 0Á0001), EBV-HLH (10Á84; 3Á84-17Á16, P < 0Á0001) and KD (3Á12; 1Á89-5Á94, P < 0Á01). There were no significant differences between HCs and acute (2.53; 0.86-7.5). The sTNF-RII/I ratio was elevated significantly in MAS compared with acute (P < 0Á0001) and KD (P < 0Á0001) and elevated significantly in EBV-HLH compared with acute (P < 0Á0001), MAS (P < 0Á05) and KD (P < 0Á0001). The sTNF-RII/I ratio was also elevated significantly in KD compared with acute (P < 0Á05). Fig. 1 . Serum soluble tumour necrosis factor receptor I (sTNF-RI) and II levels and sTNF-RII/I ratio in different patient groups. Serum levels of (a) sTNF-RI, (b) sTNF-RII and (c) sTNF-RII/I ratio from different patient groups are shown. Bars represent median values. Statistically significant differences between each patient group are shown as *P < 0Á05, **P < 0Á01, ***P < 0Á001 and ****P < 0Á0001. Acute 5 acute phase in patients with s-JIA; MAS 5 macrophage activation syndrome; EBV-HLH 5 Epstein-Barr virus-associated haemophagocytic syndrome; KD 5 Kawasaki disease; HC 5 healthy control. Receiver operating characteristic (ROC) curve analysis indicated that the optimal cut-off value of sTNF-RI, sTNF-RII and sTNF-RII/I ratio for the differentiation between acute and MAS was > 3105, > 12 250 and > 4Á562, respectively (Fig. 2) . At this level, the sensitivity was 62Á1, 89Á6 and 82Á8% and the specificity was 68Á3, 87Á5 and 92Á3%. The area under the ROC curve was 0Á6478, 0Á9201 and 0Á9466, the odds ratio was 3Á521 (95% confidence interval 5 1Á495-8Á29), 60Á67 (95% confidence interval, 16Á06-229Á2), 57Á6 (95% confidence interval, 17Á28-192Á0) and the likelihood ratio was 1Á96, 7Á172 and 10Á76.
The time-course of changes in sTNF-RII/I ratio in MAS complicating s-JIA
We compared serum sTNF-RI and II levels and the sTNF-RII/I ratio during the acute phase before developing MAS and at the time of MAS diagnosis in 16 patients with MAS complicating s-JIA, whose sera were obtained in both acute phase and MAS. As shown in Fig. 3a , serum sTNF-RI levels were not elevated during MAS compared with the acute phase. However, as shown in Fig. 3b ,c, serum sTNF-RII levels and the sTNF-RII/I ratio were elevated significantly during MAS compared with the acute phase. To investigate the relevance of the sTNF-RII/I ratio in the pathogenesis of MAS complicating s-JIA, the sTNF-RII/I ratio was serially monitored in three cases of MAS complicating s-JIA (Fig.  4a-c) . The serum sTNF-RII/I ratio increased markedly and rapidly as MAS developed.
Correlation between serum sTNF-RII/I ratio and measures of disease activity in patients with MAS complicating s-JIA Levels of serum ferritin, aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) are used clinically as indicators for disease activity of s-JIA. Furthermore, as we reported previously, serum proinflammatory cytokines, including neopterin, IL-18 and IL-6, are indicators of disease activity in s-JIA. Therefore, we assessed the correlation of the sTNF-RII/I ratio to these indicators and cytokines. The sTNF-RII/I ratio correlated positively with ferritin, AST, LDH, neopterin and IL-18 (Fig. 5a-e) , whereas the sTNF-RII/I ratio was correlated weakly negatively with IL-6 ( Fig. 5f ).
Serum IL-18 levels in patients with MAS and EBV-HLH
We measured serum IL-18 levels in patients with MAS and compared these with levels seen in patients with EBV-HLH. As shown in Fig. 6 , compared with EBV-HLH (median 5 4050; range 5 1320-14 800 pg/ml), serum IL-18 levels were elevated significantly in MAS (183 500; 30 500-830 000 pg/ml, P < 0.0001).
Discussion
MAS is a fatal complication of s-JIA caused by a massively activated but dysregulated immune response. MAS occurs in approximately 10% of patients with s-JIA; however, a much higher proportion of patients (30-40%) have complications with subclinical MAS [13, 14] . MAS is potentially life-threating if left untreated; therefore, a timely and prompt diagnosis is required to initiate appropriate lifesaving treatment. However, it is often difficult to make an Some reports have shown increased serum TNF-a levels in patients with s-JIA [15] , whereas others have shown no significant changes in serum TNF-a between patients with s-JIA and controls [16] . The reasons for these differences are unclear, but one possibility might be due to the instability of TNF-a. Conversely, sTNF-RI/II are very stable and can also be determined in stored serum. A previous report showed that serum sTNF-RI and II levels were elevated significantly in patients with s-JIA compared with HCs, even though serum TNF-a levels did not differ [16] .
In this study, as shown in Fig. 1 , serum sTNF-RI levels were elevated significantly in acute, MAS, EBV-HLH and KD compared with HCs. Serum sTNF-RII levels were also elevated significantly in patients with acute, MAS, EBV-HLH and KD compared with HCs. Furthermore, serum sTNF-RII levels were elevated significantly in MAS and EBV-HLH compared with acute and KD. Interestingly, there were no significant differences in the sTNF-RII/I ratio between HCs and acute, whereas the sTNF-RII/I ratio was elevated significantly in patients with MAS and EBV-HLH compared with acute, KD and HCs. Furthermore, as shown in Fig. 3 , the sTNF-RII/I ratio increased significantly during MAS compared with acute. As shown in Fig. 4 , the sTNF-RII/I ratio increased profoundly and rapidly as MAS developed. These findings suggest that the sTNF-RII/I ratio may represent a promising indicator of disease activity for MAS and may also be a useful marker to predict the transition to MAS from acute phase. Specifically, patients with s-JIA and sTNF-RII/I ratio > 4Á562 were at high risk of developing MAS.
As shown in Fig. 5 , the sTNF-RII/I ratio was correlated positively with measures of disease activity such as ferritin, AST and LDH as well as other proinflammatory cytokines, including neopterin and IL-18. The sTNF-RII/I ratio increased significantly in patients with severe MAS with massively elevated levels of AST, LDH and ferritin. Conversely, the sTNF-RII/I ratio was correlated negatively with IL-6. A previous report showed that TNF-a, IFN-g and IL-18 become dominant in place of IL-6 in the development of MAS from the acute phase of s-JIA [17] . TNF-a and IFN-g might play a central role in the pathogenesis of MAS rather than IL-6, although IL-6 is a key cytokine in the pathogenesis of s-JIA. Another possibility is serum IL-6 levels may be affected by treatments such as steroid and cyclosporine, because most MAS patients in this study were on medication.
In this study, the sTNF-RII/I ratio was elevated significantly in EBV-HLH and MAS. Differentiation of MAS from other causes of secondary HLH, such as EBV-HLH, is essential to select appropriate therapeutic interventions in a timely fashion. As shown in Fig. 6 , serum IL-18 levels were elevated significantly in MAS compared with those in EBV-HLH. These results indicated that serum IL-18 levels are useful to differentiate MAS from EBV-HLH.
In conclusion, the sTNF-RII/I ratio may represent a promising indicator of disease activity for MAS and may also be a useful marker for assessing the transition to MAS from acute phase. Furthermore, serum IL-18 levels is useful to differentiate MAS from EBV-HLH. Therefore, the monitoring of serum IL-18 and sTNF-RII/I might be clinically useful for the differentiation between active s-JIA, MAS and HLH. To establish the criteria for the timely diagnosis of MAS, further studies to determine the kinetics of laboratory tests and reliable biomarkers such as IL-18, sTNF-RII/ I ratio, IFN-g and IFN-g-induced chemokines, and to clarify the usefulness of panelling them, is desired.
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